Healome Therapeutics, a spinout from the University of Birmingham, is seeking regulatory engagement with both the FDA and the MHRA.
3 reports, 1 independent
Updated Jul 7
Gone quiet
Reached 3 outlets in its first 24 hours
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Healome Therapeutics, a spinout from the University of Birmingham, is seeking regulatory engagement with both the FDA and the MHRA.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
University of Birmingham
university in Birmingham, England, United Kingdom
Related events
- FDA is willing to review updated submissions, while biotech hubs leverage AI to ease clinical development bottlenecks.
- FDA approval enables commercial opportunity involving CBRE Group.
- Data was presented in Athens supporting a future U.S. NDA submission to the FDA.
- OS Therapies, Inc. is seeking interim and final review data submissions from regulatory bodies while attending major global investment conferences.
- Kazia Therapeutics Limited is seeking various regulatory designations from the FDA to support its drug development pipeline.